Gold prices steady ahead of Fed decision; weekly weakness noted
SIGA Technologies Inc. (NASDAQ:SIGA), a $460 million pharmaceutical company with a "GREAT" financial health rating according to InvestingPro, has announced amendments to its bylaws and reported on stockholder voting results from its recent annual meeting, according to a recent 8-K filing with the Securities and Exchange Commission. The company, currently trading at $6.44 per share and offering an attractive 9.5% dividend yield, appears slightly undervalued based on InvestingPro’s Fair Value analysis.
On Monday, June 10, 2025, SIGA’s Board of Directors, following the recommendation of the Nominating and Corporate Governance Committee, amended the company’s bylaws. The amendments designate the Court of Chancery of the State of Delaware as the exclusive forum for certain state corporate law or shareholder derivative claims. Additionally, they specify the federal district courts of the United States as the exclusive forum for complaints arising under the Securities Act of 1933, as amended.
During the 2025 Annual Meeting held on the same day, stockholders representing 64,026,721 shares, or 89.62% of the shares outstanding as of the April 17, 2025 record date, attended or were represented by proxy. The stockholders elected eight director nominees to serve until the 2026 Annual Meeting, ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved an amendment to the Amended and Restated Certificate of Incorporation to limit the liability of officers under certain conditions.
The election of directors saw a majority of votes cast in favor of all eight nominees. The ratification of PricewaterhouseCoopers LLP as the company’s independent auditor received a significant majority of the votes, with 62,443,679 shares voted for, 1,560,255 against, and 22,787 abstaining. The amendment to limit officer liability also passed, with 48,719,832 shares voted for, 4,251,294 against, and 18,539 abstaining.
These corporate governance updates and stockholder decisions are part of SIGA Technologies’ ongoing efforts to align its operations with industry best practices and regulatory requirements. The details of the bylaws and the voting results provide transparency to investors and stakeholders regarding the company’s governance and oversight mechanisms. With a strong current ratio of 8.4 and virtually no debt, SIGA maintains robust financial flexibility to support its corporate initiatives. InvestingPro analysis reveals 8 additional key insights about SIGA’s financial strength and market position, available to subscribers along with a comprehensive Pro Research Report covering what really matters for informed investment decisions.
The information provided in this article is based on the company’s SEC filing and enriched with financial data from InvestingPro, which shows SIGA generated $48.5 million in net income over the last twelve months, maintaining strong profitability amid its corporate governance improvements.
In other recent news, CEGA Technology reported a net loss of $1 million for the first quarter of 2025, with earnings per share at -$0.01, which did not meet analysts’ expectations. The company generated $7 million in revenue, primarily from product sales and research and development. Despite the earnings miss, CEGA Technology announced a special cash dividend of $0.60 per share, reflecting confidence in its financial health. The company delivered $53 million worth of oral TPOXX and $9 million of IV TPOXX to the U.S. Strategic National Stockpile, highlighting its strong government partnerships. CEGA Technology is advancing its Post-Exposure Prophylaxis (PEP) program, aiming for FDA submission in the first half of 2026. The U.S. government exercised an option to procure an additional $26 million of IV TPOXX, with expected delivery in 2026. The company maintains a robust cash balance of $162 million, with no debt. CEGA Technology’s future revenue forecasts for 2025 and 2026 are set at $121.6 million and $237.4 million, respectively, indicating strong growth expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.